Reuters logo
4 months ago
BRIEF-Genentech announces positive interim results for Emicizumab in phase III study of children with Hemophilia A
April 17, 2017 / 5:11 AM / 4 months ago

BRIEF-Genentech announces positive interim results for Emicizumab in phase III study of children with Hemophilia A

April 17 (Reuters) -

* Genentech announces positive interim results for Emicizumab in phase III study of children with Hemophilia A

* Genentech - results build upon data for Emicizumab in adults and adolescents with Hemophilia A and inhibitors to factor VIII

* Genentech - Emicizumab Prophylaxis reduced number of bleeds in children with Hemophilia A and inhibitors to factor VIII

Source text for Eikon:

company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below